Retatrutide’s side effect profile in Phase 2 trials looked similar to tirzepatide. The main complaints were GI: nausea, constipation, diarrhea, and burping. Most were mild to moderate and resolved within 8 to 12 weeks of starting or titrating up. Discontinuation rates due to adverse events ran around 6 to 16 percent across dose groups in the Phase 2 trial (Jastreboff et al. 2023 NEJM).<\/p>\n
Phase 3 trial data, which will include thousands of patients, hasn’t reported in full yet. The picture below is built from Jastreboff 2023, Rosenstock 2023 in Lancet (the T2D Phase 2), and earlier Phase 1 data published by Coskun et al. in Cell Metabolism 2022. Real-world data won’t exist until after approval.<\/p>\n
This article walks through what to expect at each phase, how to manage common side effects, and what symptoms mean you should call a doctor immediately. TrimRx connects patients to approved GLP-1 medications today and monitors side effects through ongoing telehealth follow-ups.<\/p>\n
At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.<\/p>\n
GI side effects dominate.<\/strong> In the Phase 2 trial of 338 adults with obesity, the most common adverse events at the 12 mg dose were:<\/p>\n Quick Answer: Nausea hit 35 to 45 percent of patients at higher doses, mostly mild to moderate and resolving within 2 to 6 weeks of each dose step<\/p>\n Placebo rates for the same events were 18.2%, 18.2%, 7.6%, 4.5%, and 1.5% respectively. The drug-attributable increase is large but most events were mild and clustered in the early weeks of each dose step.<\/p>\n By comparison, tirzepatide 15 mg in SURMOUNT-1 produced nausea in 29% of patients and diarrhea in 23%. The numbers aren’t directly comparable across trials, but retatrutide’s GI burden looks somewhat higher than tirzepatide at top doses.<\/p>\n Side effects peak in the first 1 to 3 weeks after each dose increase.<\/strong> The 2 mg starting dose causes mild symptoms in most patients. The 4 mg, 8 mg, and 12 mg steps each trigger a fresh wave of GI symptoms that usually settle within 2 weeks.<\/p>\n By week 24 of treatment, most patients have adapted to their maintenance dose and report few ongoing GI complaints. Patients who can’t reach the target dose typically stop or step down within the first 12 weeks.<\/p>\n If side effects are severe at a given step, the standard protocol pauses the next titration step for 2 to 4 extra weeks. About 15 percent of Phase 2 patients used this pause strategy and most eventually reached their target dose.<\/p>\n The biggest use points are eating habits and pacing:<\/p>\n Anti-nausea medications can help. Ondansetron is the most commonly prescribed and works within 30 to 60 minutes. Metoclopramide is sometimes used but carries a higher side effect burden and isn’t preferred. Don’t add anti-nausea meds without talking to your prescriber.<\/p>\n If nausea persists more than 2 weeks past a dose increase, that’s a sign the titration is moving too fast. Stepping back down for 4 weeks and retrying is reasonable.<\/p>\n Constipation happens because GLP-1 receptor activation slows GI motility throughout the digestive tract, not just the stomach.<\/strong> The most effective interventions are:<\/p>\n If constipation lasts more than 5 to 7 days or is painful, talk to your prescriber. Severe or persistent constipation can progress to bowel obstruction in rare cases, particularly in patients with prior abdominal surgeries.<\/p>\n Yes, in some patients, especially during the first 4 to 8 weeks of each dose step.<\/strong> The fatigue mechanism is partly the calorie deficit (you’re eating much less) and partly the metabolic shift from glucagon receptor activation increasing fat oxidation.<\/p>\n Practical fixes:<\/p>\n If fatigue is severe or accompanied by dizziness, lightheadedness, or rapid heart rate, get bloodwork. Anemia, electrolyte imbalances, and thyroid dysfunction can all worsen with rapid weight loss.<\/p>\n Rapid weight loss of any cause increases gallstone risk.<\/strong> In the Phase 2 trial, cholelithiasis was reported in 2 to 4 percent of patients on retatrutide versus 0 percent on placebo. This pattern matches what’s seen with semaglutide and tirzepatide at high doses.<\/p>\n Symptoms of a gallbladder attack include sharp right upper abdominal pain, often radiating to the back or right shoulder, nausea, and vomiting. Pain typically comes after fatty meals. If you have these symptoms, get evaluated promptly with an ultrasound.<\/p>\n Ursodeoxycholic acid (300 to 600 mg twice daily) is sometimes prescribed prophylactically for patients at high risk of gallstones during rapid weight loss, but routine use isn’t standard.<\/p>\n Key Takeaway: Pancreatitis cases in Phase 2 were rare (under 1 percent) and similar to placebo rates<\/p>\n GLP-1 drugs have carried theoretical pancreatitis concerns since the early 2010s.<\/strong> Large real-world studies of semaglutide and liraglutide have shown either no increase or very small absolute increases in pancreatitis risk. Phase 2 data for retatrutide showed pancreatitis in under 1 percent of treated patients, similar to placebo.<\/p>\n Symptoms of pancreatitis are severe upper abdominal pain that radiates to the back, nausea, and vomiting. Pain is usually steady and intense, not the cramping pattern of typical GI side effects. If you suspect pancreatitis, stop the drug and get evaluated emergently.<\/p>\n People with a history of pancreatitis were excluded from the Phase 2 trial. They should not use retatrutide off-label even if it becomes available, until safety data exists for that population.<\/p>\n Yes, by about 5 to 8 beats per minute on average at maintenance dose.<\/strong> This matches what semaglutide and tirzepatide do. The mechanism is partly direct GLP-1 effects on the sinoatrial node and partly compensation for blood pressure reductions.<\/p>\n For most patients with no preexisting cardiac issues, this isn’t clinically significant. People with atrial fibrillation, unstable arrhythmias, or recent cardiovascular events should discuss the heart rate increase with cardiology before starting.<\/p>\n The SELECT trial of semaglutide (Lincoff et al. 2023 NEJM) showed 20% reduction in major cardiovascular events despite the heart rate increase, suggesting the net cardiovascular effect of GLP-1-class drugs is strongly beneficial for high-risk patients.<\/p>\n In rodent studies, GLP-1 receptor agonists including retatrutide cause medullary thyroid cancer (MTC) at high doses.<\/strong> Human studies have not shown an increased MTC risk, but the boxed warning persists on all GLP-1 drug labels.<\/p>\n Patients with a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2 (MEN 2) should not take retatrutide. Routine calcitonin monitoring isn’t recommended unless there’s a clinical reason to investigate.<\/p>\n Call the same day or sooner if you have:<\/p>\n For routine GI side effects that are mild to moderate, telehealth follow-up within a few days is usually enough.<\/p>\n Standard monitoring during GLP-1 treatment includes:<\/p>\n Phase 3 trials are also tracking bone density (DEXA) given concerns about lean mass loss during rapid weight loss. Routine DEXA monitoring isn’t standard outside of trials but may be useful for high-risk patients.<\/p>\n Bottom line: No cases of medullary thyroid cancer reported in Phase 2, though rodent data triggered the same boxed warning planned for retatrutide labeling as other GLP-1s<\/p>\n Yes, in most patients. The first 2 weeks of each dose step are the hardest. By week 24 of treatment, most patients have minimal ongoing GI symptoms at their maintenance dose.<\/p>\n Yes. There’s no major drug interaction between GLP-1 drugs and PPIs or H2 blockers. Some patients find that low-dose famotidine helps with the burping and reflux that occasionally show up with delayed gastric emptying.<\/p>\n Hair shedding can happen with rapid weight loss from any cause, including retatrutide. It’s not a direct drug effect. Adequate protein intake, iron, biotin, and zinc help, and the shedding usually resolves 3 to 6 months after weight stabilizes.<\/p>\n Some, yes. DEXA substudies in Phase 2 showed roughly 30 percent of total weight lost was lean tissue. Resistance training 2 to 3 times a week and protein intake of 1.2 to 1.6 g\/kg of body weight cut lean mass loss meaningfully.<\/p>\n Phase 2 data didn’t show a depression signal. Some individual patients report mood shifts during rapid weight loss, which may be due to caloric restriction and metabolic changes rather than the drug itself. SELECT trial data on semaglutide was reassuring on suicidal ideation.<\/p>\n For non-diabetics, very low. For patients on insulin or sulfonylureas, yes. Those medications usually need to be reduced when starting any GLP-1 drug, and retatrutide is no exception.<\/p>\n Anaphylaxis to the peptide or excipients has occurred with GLP-1 drugs in single-digit cases per million doses. Severe allergic reactions warrant immediate emergency care.<\/p>\n Disclaimer:<\/strong> This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.<\/p>\n","protected":false},"excerpt":{"rendered":" Retatrutide’s side effect profile in Phase 2 trials looked similar to tirzepatide.<\/p>\n","protected":false},"author":11,"featured_media":93279,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"_yoast_wpseo_title":"Retatrutide Side Effects: Complete Profile, Management & When to Call Your Doctor","_yoast_wpseo_metadesc":"Retatrutide's side effect profile in Phase 2 trials looked similar to tirzepatide.","_yoast_wpseo_focuskw":"retatrutide side effects","footnotes":"","_flyrank_wpseo_metadesc":""},"categories":[6],"tags":[43],"class_list":["post-90503","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-glp-1","tag-retatrutide"],"_links":{"self":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/90503","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/comments?post=90503"}],"version-history":[{"count":3,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/90503\/revisions"}],"predecessor-version":[{"id":92511,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/90503\/revisions\/92511"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media\/93279"}],"wp:attachment":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media?parent=90503"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/categories?post=90503"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/tags?post=90503"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}\n
When Do Retatrutide Side Effects Peak?<\/h2>\n
How Do I Manage Retatrutide-related Nausea?<\/h2>\n
\n
How Do I Deal with Constipation on Retatrutide?<\/h2>\n
\n
Does Retatrutide Cause Fatigue?<\/h2>\n
\n
What About Retatrutide and Gallstones?<\/h2>\n
Is Pancreatitis a Real Risk with Retatrutide?<\/h2>\n
Does Retatrutide Increase Heart Rate?<\/h2>\n
What Is the Thyroid Cancer Warning About?<\/h2>\n
When Should I Call My Doctor About Retatrutide Side Effects?<\/h2>\n
\n
What Lab Work Should I Get on Retatrutide?<\/h2>\n
\n
FAQ<\/h2>\n
Will Side Effects Go Away?<\/h3>\n
Can I Take Retatrutide with an Antacid?<\/h3>\n
Is Hair Loss a Side Effect of Retatrutide?<\/h3>\n
Will I Lose Muscle on Retatrutide?<\/h3>\n
Does Retatrutide Cause Depression or Mood Changes?<\/h3>\n
Is There a Risk of Low Blood Sugar?<\/h3>\n
What’s the Rarest Serious Side Effect?<\/h3>\n